Hospital
Penobscot Valley Hospital
Penobscot Valley Hospital was paid $1.28M by Medicaid between Jan 2018 and Dec 2024, across 118 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 22% of everything it billed.
33Billing provider infoPENOBSCOT VALLEY HOSPITAL
LINCOLN, ME 04457
LINCOLN, ME 04457
33aNPI1093716086assigned 08/02/2005
33bProvider typeCritical Access Hospital
28Total paid$1.28M
24GClaims177,629
24DCodes billed118
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#9 of 14
Median peer was paid$1.76M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,771 | $175K | |
| 2019 | 24,054 | $168K | |
| 2020 | 22,825 | $169K | |
| 2021 | 22,711 | $173K | |
| 2022 | 25,427 | $180K | |
| 2023 | 30,440 | $218K | |
| 2024incomplete | 29,401 | $193K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 22% | 1,354 | 1,265 | $278K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 15,085 | 9,459 | $221K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.9% | 17,076 | 10,795 | $126K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.5% | 3,885 | 2,768 | $121K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.2% | 1,541 | 1,413 | $118K |
| 71046 | Radiologic examination, chest; 2 views | 4.2% | 3,695 | 3,365 | $54K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 10,820 | 3,092 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 4,818 | 4,131 | $37K |
| 80053 | Comprehensive metabolic panel | 2.0% | 13,078 | 10,953 | $25K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 183 | 175 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 15,146 | 12,127 | $18K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 1,525 | 1,360 | $18K |
106 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 165 | $17K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 5,330 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 338 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,739 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,386 | $8K |
| 71250 | <1% | 71 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 970 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,952 | $7K |
| 84484 | <1% | 3,896 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 256 | $5K |
| 93307 | <1% | 32 | $4K | |
| 73030 | <1% | 180 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,323 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,097 | $4K |
| 97162 | <1% | 532 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 692 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,949 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 290 | $3K |
| 72100 | <1% | 110 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 812 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 926 | $3K |
| 87631 | <1% | 1,746 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,224 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,111 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 107 | $2K |
| 83735 | <1% | 3,648 | $2K | |
| 85610 | <1% | 2,977 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 118 | $2K |
| 81001 | <1% | 3,478 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,318 | $2K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 185 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 555 | $2K |
| 71271 | <1% | 26 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 256 | $2K |
| 83880 | <1% | 387 | $2K | |
| 83690 | <1% | 2,388 | $1K | |
| 73630 | <1% | 143 | $1K | |
| 73564 | <1% | 93 | $1K | |
| 83605 | <1% | 1,442 | $1K | |
| 85027 | <1% | 4,252 | $1K | |
| 80061 | Lipid panel | <1% | 2,086 | $1K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 508 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 525 | $1K |
| 81003 | <1% | 2,157 | $964.41 | |
| 82948 | <1% | 1,840 | $961.23 | |
| 86140 | <1% | 1,779 | $865.06 | |
| 97161 | <1% | 77 | $845.34 | |
| 87186 | <1% | 928 | $831.74 | |
| 82043 | <1% | 245 | $797.13 | |
| 73610 | <1% | 91 | $722.31 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 459 | $701.76 |
| 84439 | <1% | 433 | $695.73 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,995 | $670.39 |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $654.76 |
| 85379 | <1% | 582 | $637.84 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 49 | $611.33 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 143 | $563.86 |
| Q3014 | Telehealth originating site facility fee | <1% | 497 | $514.33 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 342 | $500.14 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 894 | $469.48 |
| 85004 | <1% | 120 | $465.89 | |
| 87040 | <1% | 313 | $451.89 | |
| 82728 | <1% | 350 | $449.92 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 734 | $449.67 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,563 | $419.55 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,287 | $375.01 |
| 85730 | <1% | 201 | $373.03 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 405 | $361.87 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 99 | $338.25 |
| 73502 | <1% | 16 | $317.01 | |
| 82607 | <1% | 118 | $307.12 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 204 | $300.05 |
| 84100 | <1% | 261 | $238.39 | |
| 83540 | <1% | 217 | $222.12 | |
| 83550 | <1% | 171 | $206.07 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 244 | $192.46 |
| 85651 | <1% | 212 | $175.33 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 826 | $164.37 |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $135.55 |
| 99217 | <1% | 27 | $119.40 | |
| 90715 | <1% | 12 | $119.38 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 160 | $116.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 84 | $107.21 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 65 | $106.74 |
| 73110 | <1% | 31 | $92.65 | |
| 87077 | <1% | 68 | $63.33 | |
| 80305 | <1% | 184 | $61.42 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 27 | $53.22 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 43 | $51.70 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 37 | $41.10 |
| 87081 | <1% | 365 | $33.51 | |
| 87088 | <1% | 76 | $31.83 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17 | $27.63 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 34 | $27.59 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 14 | $21.40 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 12 | $18.72 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 18 | $15.04 |
| 81025 | <1% | 302 | $5.78 | |
| 82570 | <1% | 31 | $4.02 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 27 | $2.01 |
| 85008 | <1% | 61 | $1.71 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 105 | $0.31 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 46 | $0.06 |
| 90837 | Psychotherapy session, about an hour | 0% | 39 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPELKEY, MELISSA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Penobscot Valley Hospital | Lincoln, ME | $1.05M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.